Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trial Group study.
Maroun
J A
JA
Ottawa Regional Cancer Centre, Canada.
Skillings
J
J
MacCormick
R
R
Potvin
M
M
Wielgosz
G
G
Davidson
J R
JR
Eisenhauer
E
E
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011720:Pyrazoles / Q000627:therapeutic use*
D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046658:teloxantrone